Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  HCV Coinfection HIV Infection HIV infection. 2. Infection with HCV genotype 4. 3. No prior treatment with any interferon or no response to a previous treatment with Peg-IFN plus RBV. The lack of response will both nonresponders, and those who showed relapse. 4. Stable antiretroviral therapy 24 weeks before starting the study drugs, with undetectable plasma HIV RNA during that period of time. 5. Commitment to use two non-hormonal contraception during the study and up to 24 weeks after treatment. 6. Acceptance to give written informed consent to participate in the trial  Antiretroviral therapy including didanosine, stavudine, zidovudine and abacavir. 2. Decompensated cirrhosis. 3. Presence of other significant liver diseases, including chronic hepatitis or acute hepatitis B, acute hepatitis hepatitis A, hemochromatosis or deficiency of alpha-1 antitrypsin. 4. Pregnancy and lactation. 5. Men planning pregnancy with their partners during the study and up to 24 weeks after treatment. 6. Active or uncontrolled depression, other psychiatric illness, or disease during the previous year which may, in the investigator's opinion, prevent participation in the study. 7. Previous suicide attempt. 8. Active thyroid disease or poorly controlled with treatment. 9. Previous autoimmune diseases such as inflammatory bowel disease, psoriasis serious, or rheumatoid arthritis, which may be exacerbated by interferon. 10. Chemotherapy or immunomodulatory 24 weeks before starting the study. 11. Serious illness, including cancer or unstable coronary disease, 24 weeks before starting the study. 12. Any chronic disease which, in the opinion of the investigator, may prevent complete the study. 13. Presence of acute or active opportunistic infections 48 weeks before starting the study. 14. Evidence of hepatocellular carcinoma or alpha-fetoprotein levels ≥ 50 ng / ml, unless an imaging technique shows no evidence of liver tumor, all obtained 24 weeks before starting the study. 15. Hemoglobinopathy or other conditions that may facilitate hemolysis. 16. Solid organ or bone marrow transplant. 17. Known hypersensitivity to any of the drugs under study. 18. Active consumption of drugs or alcohol in the opinion of the investigator would interfere with participation in the study. The use of methadone or other opiate replacement therapy is not considered an criterion. 19. Serious side effects from treatment with Peg-IFN plus RBV in patients with prior failure of such treatment